Aggressive treatment for some stage 4 lung cancer patients improves survival

17 Sep 2014

Aggressive treatment for some "low risk" patients with stage 4 non-small cell lung cancer (NSCLC) led to an improved 5-year overall survival rate of 47.8%, as shown in an large international analysis.

The study results also indicate that a patient's overall survival rate can be related to factors including the timing of when metastases develop and lymph node involvement. This research was presented at the American Society for Radiation Oncology's (ASTRO's) 56th Annual Meeting.

Metastatic lung cancer

When lung cancer has spread from an original tumor to other sites of the body, it is classified as metastatic (Stage 4), and the goal of treatment is to slow the cancer down with chemotherapy or radiation, but these treatments are unable to eradicate the cancer and survival is usually in the range of only a few months.

However, when there are only a few locations of metastatic lung cancer (called oligo-metastatic), some studies suggest that by removing or eradicating each of those cancer deposits with aggressive treatments such as surgery or high-dose, precise radiation called stereotactic ablative radiotherapy or SABR, the cancer may be controlled for a long period of time.

Study of 757 patients worldwide

In order to further study the possible benefits of aggressive treatments in stage IV lung cancer, researchers completed this meta-analysis which evaluated data of 757 Stage 4 NSCLC patients from 20 hospitals worldwide who had between one and five metastatic deposits that were removed surgically or eradicated with high-dose, precise radiotherapy.

Patients in the study also had to have had aggressive treatment of their original lung tumor.

The intent of the study was to determine whether long term survivors exist after aggressive treatment of oligo-metastases, and to propose a risk classification scheme that could be used to identify which stage 4 patients are most likely to benefit from aggressive treatments.

Study outcomes: overall survival and its factors

The analysis determined that the factors that impacted overall survival of the patients included the timing of when the metastases appeared, that is, whether the metastases appeared at the same time as the original lung cancer (synchronous) vs. if they appeared after the original lung cancer (metachronous), whether lymph nodes in the chest were involved (N-stage), and the type of lung cancer (adenocarcinoma vs. other types).

Using these factors, and in terms of Overall Survival (OS), the study identified three risk groups of patients

  1. low risk patients (146), or patients who survived the longest, were those with metachronous metastases, with a 5 year OS of 47.8%
  2. intermediate-risk patients (201)—those with synchronous metastases and no evidence of involved lymph nodes in the chest, with a 5-year OS of 36.2%
  3. high-risk patients (184), or patients with the poorest survival, were those who had synchronous metastases and evidence of lymph node involvement in the chest; they had a five-year OS of 13.8%.

Furthermore, the study found that despite receiving aggressive treatments, more than half of the patients progressed in previously treated areas or developed new sites of disease within one year of treatment.

Lead study author: more research necessary

"Our study finds some stage IV NSCLC patients can achieve long-term survival after aggressive treatments; however, it is important to note that the patients in this study are a very select minority of stage IV patients who are younger, more physically fit, with a lower burden and slower pace of disease than the average stage IV patient," said lead study author Allison Ashworth, MD, a radiation oncologist who completed the study as part of her training at the London Health Sciences Centre at Western University, in London, Ontario.

"We hope our study's results will help determine which stage IV NSCLC patients are most likely to benefit from aggressive treatments, and equally as important, help identify those patients most likely to fail, thus sparing them from futile and potentially harmful treatments. Our research, however, cannot answer the question of whether the longer survival is due to the treatments or simply because these patients have less aggressive disease. We must await the results of randomized clinical trials to answer this question. In the meantime, it is our hope that our study will help cancer specialists in making treatment decisions and in the development of clinical trials."

 

Source: eCancer News

No Comment